Endocrine Abstracts

Background: Previous studies have yielded conflicting results on biochemical control with medical therapy in patients with or without prior pituitary surgery. The LANTERN study (NCT02493517) demonstrated that lanreotide autogel (LAN ATG) was non-inferior to lanreotide prolonged release (LAN PR) in Chinese patients with active acromegaly. This post hoc analysis of the LANTERN study aimed to explore the efficacy of LAN ATG in patients with or without prior pituitary surgery....

Background: The LANTERN study (NCT02493517) has demonstrated that lanreotide autogel (LAN ATG) was non-inferior to lanreotide prolonged release (LAN PR) in Chinese patients with active acromegaly. This post hoc analysis of the LANTERN study assessed the impact of tumor size on treatment effect.Design: In the LANTERN study, LAN ATG was started at 90 mg and subsequently titrated according to GH and IGF-1 levels for 32 weeks. Tumor diameters > 10 mm wer...